Literature DB >> 7979104

Laboratory evaluation of the DCA 2000 clinic HbA1c immunoassay analyser.

W G John1, R Edwards, C P Price.   

Abstract

The DCA 2000 clinical analyser for the measurement of haemoglobin A1c was evaluated for analytical quality. The analyser, which utilises inhibition of latex agglutination immunoassay, demonstrated good within-batch (1.9-3.1% CV) and between-batch (2.2% CV) imprecision, and was not affected by haemoglobin concentration. The analyser was linear throughout the analytical range, and was found to correlate well with agar electroendosmosis (r = 0.93), affinity chromatography (r = 0.97), HPLC (r = 0.90) and EIA (r = 0.98). The analyser was found to give reliable analytical results, and with its ease of use, will provide the diabetologist with HbA1c results in the clinic; although an analysis time of 9 min will limit sample throughput.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979104     DOI: 10.1177/000456329403100411

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  14 in total

1.  Comparison between a rapid glycohaemoglobin (HbA1c) immunoassay and other indices of glycaemic control.

Authors:  E Le Marois; F Bruzzo; G Reach; F Guyon; J Luo; J Boillot; G Slama; J L Selam
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

2.  Results of an innovative education, training and quality assurance program for point-of-care HbA1c testing using the Bayer DCA 2000 in Australian Aboriginal Community Controlled Health Services.

Authors:  Mark D Shephard; Janice P Gill
Journal:  Clin Biochem Rev       Date:  2003-11

3.  Rationale, design, and baseline characteristics of a community-based comparative effectiveness trial to prevent type 2 diabetes in economically disadvantaged adults: the RAPID Study.

Authors:  Ronald T Ackermann; Emily A Finch; Karen K Schmidt; Helena M Hoen; Laura M Hays; David G Marrero; Chandan Saha
Journal:  Contemp Clin Trials       Date:  2013-10-29       Impact factor: 2.226

4.  One-year effects of a group-based lifestyle intervention in adults with type 2 diabetes: A randomized encouragement trial.

Authors:  David T Liss; Emily A Finch; Andrew Cooper; Avani Sheth; Ashantí D Tejuosho; Nicola Lancki; Ronald T Ackermann
Journal:  Diabetes Res Clin Pract       Date:  2018-03-27       Impact factor: 5.602

Review 5.  A review of the challenge in measuring hemoglobin A1c.

Authors:  Cas Weykamp; W Garry John; Andrea Mosca
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

6.  A Randomized Comparative Effectiveness Trial for Preventing Type 2 Diabetes.

Authors:  Ronald T Ackermann; David T Liss; Emily A Finch; Karen K Schmidt; Laura M Hays; David G Marrero; Chandan Saha
Journal:  Am J Public Health       Date:  2015-09-17       Impact factor: 9.308

7.  Design and participant characteristics for a randomized effectiveness trial of an intensive lifestyle intervention to reduce cardiovascular risk in adults with type 2 diabetes: The I-D-HEALTH study.

Authors:  David T Liss; Emily A Finch; Dyanna L Gregory; Andrew Cooper; Ronald T Ackermann
Journal:  Contemp Clin Trials       Date:  2015-12-02       Impact factor: 2.226

8.  Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study.

Authors:  Ronald T Ackermann; Emily A Finch; Edward Brizendine; Honghong Zhou; David G Marrero
Journal:  Am J Prev Med       Date:  2008-10       Impact factor: 5.043

9.  HbA1c standardisation: history, science and politics.

Authors:  W Garry John; Andrea Mosca; Cas Weykamp; Ian Goodall
Journal:  Clin Biochem Rev       Date:  2007-11

10.  Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: the DEPLOY pilot study.

Authors:  Elaine R Lipscomb; Emily A Finch; Edward Brizendine; Chandan K Saha; Laura M Hays; Ronald T Ackermann
Journal:  Diabetes Care       Date:  2008-12-23       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.